Glenmark Pharmaceuticals (Glenmark), a manufacturer of generic formulation products and API, has been granted tentative approval by the United States Food & Drug Administration (US FDA) for Calcipotriene Cream, 0.005%, the therapeutic equivalent of Dovonex Topical Cream, 0.005% of Leo Pharma A/S Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA.

The patents listed in the Orange Book for Dovonex Cream are scheduled to expire on June9,2015.Dovonex is indicated for the treatment of plaque psoriasis.

According to IMS Health sales data for the 12 month period ending March 2015, the Dovonex market achieved annual sales of approximately USD 92.8 million.

Shares of the company gained Rs 9.7, or 1.09%, to trade at  Rs 900.  The total volume of shares traded  was  7,646 at the BSE (9.31 a.m., Monday).